14th International Pharma Licensing Symposium
The program features the theme of Peak Performance, which is designed to help Business Development and M&A executives to evolve their deal-making in an ever-changing Business Development environment.
Kempen’s talk on Friday September 21st is about ‘Designing the optimal exit strategy: IPO, M&A or dual track?’ presented by Nadine Maalouf, Executive Director Corporate Finance, Life Sciences & Healthcare.
More on
More information? Contact
